Heidi A. Dare
Heidi counsels clients in patent related matters including international patent portfolio management and due diligence analyses. Heidi’s practice focuses on patent prosecution in technical areas of molecular biology, medical device and medical diagnostics. Heidi’s prosecution experience includes preparing and prosecuting applications in technologies including RNA interference, recombinant nucleic acid and protein technologies, mutational analysis, antibody therapies, transgenic animals and plants, therapeutic vectors, stem cell therapies, and gene therapy. 

Heidi counsels a diverse group of clients from corporate clients of all sizes, university clients and start-ups. Heidi has prosecuted over 1000 patent applications in the U.S. and worldwide.

Prior to joining the firm in 2002, Heidi’s non-legal experience included research positions at Howard Hughes Medical Institute, University of Michigan and the Ohio State University.

  • J.D.,
    Wayne State University Law School, 2002
  • M.S., Microbiology & Immunology,
    密西根大学, 1988
  • B.A., Biology,
    Albion College, 1985
  • Illinois
  • U.S. Patent & Trademark Office
  • Biopharma
经验 | Legal

Brinks Gilson & Lione, Chicago, Illinois
Shareholder, January 2011-Present
Associate, September 2002-December 2010 

Brooks & Kushman, P.C., Southfield, Michigan
Law Clerk, May 2001-April 2002
Supported ongoing patent prosecution and litigation, including provisional applications and trademark litigation

University of Michigan, Office of the General Counsel, Ann Arbor, Michigan
Law Clerk, 2000-2001
Researched issues for all areas of law, including patent law, copyrights, contracts, UCITA, Title IX, civil rights and property

Authored Patents
  • U.S. 7,456,015: Tetracycline-Regulated Adeno-Associated Viral (AAV) Vectors for Gene Delivery to the Nervous System
  • E.P. 1,799,826 B1: siRNA-Mediated Silencing of a-Synuclein

Authored Published Patent Applications

  • U.S. 2006/0118189: Flow Variation Valve Assembly
  • U.S. 2007/0172462: siRNA-Mediated Gene Silencing of Synuclein
  • U.S. 2007/0178071: Stem-Cell, Precursor Cell, or Target Cell-Based Treatment of Multiorgan Failure and Renal Dysfunction
  • U.S. 2008/0027413: Blood Products from Mesenchymal Stem Cells
  • U.S. 2008/0051721: Loop Tip Wire Guide
  • U.S. 2008/0241112: Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
  • U.S. 2008/0306465: Adjustable Length Catheter
October 24, 2018

CHICAGO—Brinks shareholder Gary M. Ropski has been named the #1 Leading Intellectual Property Lawyer in Illinois and  Laura Beth Miller has been recognized among the Top...

June 06, 2017

CHICAGO—Intellectual property law firm Brinks Gilson & Lione has been recognized for the ninth year in a row as a top U.S. firm for patent prosecution, including for re-examination and post-grant proceedings, by The Legal 500 United States 2017...

October 23, 2014
CHICAGO—Gary M. Ropski, a shareholder at intellectual property law firm Brinks Gilson & Lione and the firm's past president, has been named the #1 Leading Intellectual Property Lawyer in Illinois by Leading Lawyers, and fifty-nine ...
  • Recommended Lawyer, Legal 500, 2017
  • Leading Intellectual Property Lawyer, Leading Lawyers Network, 2012-2016
  • American Bar Association
  • Illinois Biotechnology Industry Organization (iBIO)